| Autor: |
Ye, Zhu, Ze-Liang, Li, Ao, Ding, Hui, Yang, Wei-Ping, Zhu, Tong-Xia, Cui, Hui-Tao, Zhang, Hua, Zhang |
| Rok vydání: |
2019 |
| Předmět: |
|
| Zdroj: |
Drug Design, Development and Therapy |
| ISSN: |
1177-8881 |
| Popis: |
Background Diabetic nephropathy (DN) is a common complication of diabetes mellitus (DM) and also a major cause of end-stage renal disease (ESRD). Olmesartan medoxomil (OM) is an angiotensin II receptor blocker (ARB) and has been shown to exhibit renoprotective effects on a streptozotocin (STZ)-induced diabetic rat model. Yet, whether OM affects DN progression and renal injury in db/db mice, a type 2 diabetic murine model, has not been established. Methods Wild-type (n = 15) and db/db mice (n = 15) were treated with control saline or OM via oral gavage. The physiological and biochemical parameters were evaluated and histological examinations of kidney specimens were performed. Results Compared with saline-treated db/db mice, db/db mice administered with OM showed ameliorated diabetic physiological and biochemical parameters. In addition, OM decreased urinary albumin excretion and plasma creatinine level in db/db mice. Moreover, histologically, OM reduced glomerular hypertrophy and injury, and also ameliorated tubular injury, thus suggesting that OM improves renal function and minimizes renal pathological deterioration in db/db mice. Conclusion Our study reveals a beneficial role of OM in ameliorating DN in db/db mice, which is associated with its renoprotective function. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
